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ARTICLE
Vascular niche IL-6 induces alternative
macrophage activation in glioblastoma through
HIF-2α
Qirui Wang1,2, Zhenqiang He1,3, Menggui Huang1, Tianrun Liu1,4, Yanling Wang1, Haineng Xu1, Hao Duan1,3,
Peihong Ma1, Lin Zhang 5, Scott S. Zamvil6, Juan Hidalgo 7, Zhenfeng Zhang 8, Donald M. O’Rourke9,
Nadia Dahmane9, Steven Brem9, Yonggao Mou3, Yanqing Gong10 & Yi Fan1,9
Spatiotemporal regulation of tumor immunity remains largely unexplored. Here we identify a
vascular niche that controls alternative macrophage activation in glioblastoma (GBM). We
show that tumor-promoting macrophages are spatially proximate to GBM-associated
endothelial cells (ECs), permissive for angiocrine-induced macrophage polarization. We
identify ECs as one of the major sources for interleukin-6 (IL-6) expression in GBM micro-
environment. Furthermore, we reveal that colony-stimulating factor-1 and angiocrine IL-6
induce robust arginase-1 expression and macrophage alternative activation, mediated through
peroxisome proliferator-activated receptor-γ-dependent transcriptional activation of hypoxia-
inducible factor-2α. Finally, utilizing a genetic murine GBM model, we show that EC-specific
knockout of IL-6 inhibits macrophage alternative activation and improves survival in the
GBM-bearing mice. These findings illustrate a vascular niche-dependent mechanism for
alternative macrophage activation and cancer progression, and suggest that targeting
endothelial IL-6 may offer a selective and efficient therapeutic strategy for GBM, and possibly
other solid malignant tumors.
DOI: 10.1038/s41467-018-03050-0 OPEN
1 Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. 2 School of Traditional Chinese
Medicine, Southern Medical University, 510515 Guangzhou, China. 3 Department of Neurosurgery, Sun Yat-sen University Cancer Center, 510060
Guangzhou, China. 4 Department of Otorhinolaryngology, Division of Head and Neck Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, 510655
Guangzhou, China. 5 Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
6Department of Neurology and Program in Immunology, University of California at San Francisco, San Francisco, CA 94158, USA. 7Department of Cellular
Biology, Physiology, and Immunology, Autonomous University of Barcelona, 08193 Barcelona, Spain. 8Department of Radiology The, Second Affiliated
Hospital of Guangzhou Medical University, 510260 Guangzhou, China. 9 Department of Neurosurgery, University of Pennsylvania Perelman School of
Medicine, Philadelphia, PA 19104, USA. 10 Department of Medicine, Division of Human Genetics and Translational Medicine, University of Pennsylvania
Perelman School of Medicine, Philadelphia, PA 19104, USA. Correspondence and requests for materials should be addressed to
Y.F. (email: fanyi@uphs.upenn.edu)
NATURE COMMUNICATIONS |  (2018) 9:559 |DOI: 10.1038/s41467-018-03050-0 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Most malignant solid tumors are characterized byextensive infiltration of inflammatory leukocytes.Among them, tumor-associated macrophages play a
pivotal role in tumor growth, cancer immunosuppression, and
therapy resistance1–3. In contrast to classically activated macro-
phages that stimulate phagocytosis, inflammation, and host
immunity, a prominent population of macrophages in tumor
microenvironment undergoes alternative activation to acquire
tumor-promoting functions, for example, these macrophages
express anti-inflammatory cytokines, such as interleukin-10 (IL-
10), and tumor growth factor-β (TGF-β), and arginase-1 that
inhibits nitric oxide (NO) production and produces ornithine4–7.
Growing evidence suggests that alternative macrophage activation
is a driving force that fuels cancer progression, but the underlying
tumor microenvironment-dependent mechanisms remain largely
unknown.
Glioblastoma multiforme (GBM), the grade IV glioma, is the
most common and most aggressive primary brain tumor. GBM is
among the most lethal of human malignancies, with a current
median overall survival of approximately 14 months8, 9, largely
due to its high resistance to standard-of-care treatments including
surgical resection, radiation, and chemotherapy10. The develop-
ment of new therapies is therefore urgently needed, in which
targeting tumor immunity holds great promise for GBM treat-
ment. Notably, macrophages are a major population of the non-
neoplastic cells in GBM, evidenced by as many as half of the cells
in GBM tumors are macrophages or microglia11, 12, suggesting
that tumor-associated macrophages may represent an indis-
pensable target for immunotherapy. Likewise, a recent study
shows that receptor inhibition of colony-stimulating factor-1
(CSF-1), a major factor for macrophage differentiation and sur-
vival, alters alternative macrophage polarization and blocks GBM
progression13.
A multitude of evidence shows that macrophages stimulate
glioma growth and invasion and induce therapeutic
resistance12, 14. Glioma-associated macrophages express and
secrete multiple factors including STI1, EGF (epidermal growth
factor), TGF-β, and MT1-MMP to promote glioma cell survival,
proliferation, and migration15–19. On the other hand, glioma cells
induce macrophage recruitment by releasing chemoattractants
CXCL12, GDNF, and CSF-119–21. However, how macrophage
activation is spatiotemporally regulated in glioma is largely
unclear, which is critical for the development of new therapies
against GBM. Here, we reveal a vascular niche-dependent reg-
ulatory system for macrophage activation, targeting which may
offer new therapeutic opportunities for the treatment of GBM,
and possibly other solid malignant tumors.
Results
Vasculature-associated alternative macrophage activation. We
investigated potential alternative macrophage activation in
human GBM tumors. Although there are currently no specific
surface markers identified for distinct macrophage activation,
alternatively activated macrophages reliably express CD206 and
CD163 (and anti-inflammatory cytokine IL-10), in contrast to the
expression of CD86 (and proinflammatory cytokine IL-12) by
classically activated macrophages4, 22. Immunofluorescence ana-
lysis of surgical tumor specimens from human patients with
different grades of gliomas showed that a large population of
GBM-associated CD68+ macrophages robustly expressed CD206
and CD163 (Fig. 1a, b) and relatively expressed CD86 at a lower
level (Supplementary Fig. 1), while only small population of
CD68+ macrophages or microglia cells expressed CD206 in
normal brains (Supplementary Fig. 1). Moreover, consistent with
previously published work showing that glioma grades correlate
with the expression of multiple alternative activation markers in
tumor-associated macrophages23, there was an increase in CD206
expression by tumor-associated macrophages from different
grades of gliomas (Fig. 1c), suggesting enhanced alternative
activation in these macrophages. As a critical marker for the anti-
inflammatory macrophage subset, arginase-1 competes with
inducible nitric oxide synthase (iNOS) and hydrolyzes L-arginine
into urea and ornithine, a precursor to L-proline and polyamines,
which suppress NO-mediated cytotoxicity via L-arginine con-
sumption, enhance collagen synthesis and fibrosis via L-ornithine
formation, and increase cellular proliferation via polyamine
generation, all important for macrophage-mediated tumor-pro-
moting functions24, 25. Our data indicate that a majority of GBM-
associated macrophages expressed arginase-1 (Supplementary
Fig. 2), verifying the increased alternative activation of macro-
phages in GBM.
Interestingly, immunofluorescence analysis of these human
specimens indicated that CD206+CD68+ macrophages were
localized proximately to CD31+ vascular endothelial cells (ECs)
(Fig. 1d). To spatially precisely analyze their distribution, we took
advantage of a fluorescence protein-based genetic labeling system
to visualize the vasculature, in which tdTomato expression is
driven by EC-specific Tie2 promoter in mice (Fig. 1e). An
orthotopic, genetic murine GBM model with a native micro-
environment was induced by RCAS/N-tva-mediated somatic
PDGF gene transfer in Ink4a-Arf−/−;Pten−/− neural stem/
progenitor cells, followed by tumor transplantation into the
Tie2-Cre;ROSA-LSL-tdTomato mice (Fig. 1f). Consistent with the
observations in human subjects, three-dimensional reconvolution
of confocal scanning images showed that F4/80+CD206+ macro-
phages were localized near the tdTomato+ ECs (Fig. 1f and
Supplementary Movie 1), implicating a possible role of tumor-
associated ECs in alternative macrophage activation in GBM.
Glioma ECs promote alternative macrophage polarization. To
test the role of tumor-associated ECs in macrophage alternative
activation, we pretreated mouse ECs with the conditioned med-
ium (CM) harvested from the medium supernatant of cultured
mouse GL26 glioma cells, and co-cultured these ECs with mouse
bone marrow (BM) cells. CD11b+ macrophages were analyzed by
flow cytometry for macrophage activation. Our data revealed that
co-culture with control ECs, and to a greater extent, with glioma-
CM-pretreated ECs, induced robust CD206 expression: notably,
over 60% of CD11b+ macrophages positively expressed CD206
when co-cultured with glioma-CM-pretreated ECs, implicating
that glioma microenvironment-stimulated ECs promote alter-
native activation of macrophage (Fig. 2a). In contrast, both CSF-1
treatment and co-culture with ECs induced comparable CD86
expression in CD11b+ macrophages. Additionally, the robust
CD206 expression in macrophages induced by co-cultured
glioma-CM-pretreated ECs was validated by immuno-
fluorescence (Supplementary Fig. 3). To specifically analyze
classically and alternatively activated macrophages, we sorted
CD11b+CD86+CD206− and CD11b+CD86−CD206+, respectively.
Our data showed that glioma-CM-pretreated ECs trend to induce
alternative macrophage activation (Fig. 2b). To verify these results
in human subjects, we pretreated human brain ECs with the CM
harvested from the medium supernatant of cultured human GBM
cells, and co-cultured these cells with human peripheral blood
mononuclear cell (PBMC)-derived monocytes, followed by flow
cytometry analysis. Consistent with the results from mouse stu-
dies, we showed that glioma-CM-pretreated human ECs stimu-
lated human monocytes toward alternative activation, as
evidenced by increased CD206+CD86+ populations in CD11b+
cells (Fig. 2c). In addition, our data showed that glioma-CM alone
slightly induced CD206 expression and macrophage alternative
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activation in human monocytes under normoxia, but moderately
stimulated CD206 expression and alternative activation under
hypoxia (Supplementary Fig. 4), implicating a possible role of
hypoxia in macrophage polarization. However, hypoxia slightly
promoted macrophage alternative activation but did not further
enhance tumor EC-induced CD206 expression and alternative
activation (Supplementary Fig. 5).
Moreover, PBMC-derived monocytes were co-cultured in
transwells with normal brain ECs or GBM-associated ECs that
were isolated from human GBM specimens. Immunoblot analysis
shows that co-culture with GBM ECs induced robust arginase-1
expression in human monocytes (Fig. 2d), validating the
stimulatory effects of tumor-associated ECs on alternative
polarization of macrophages. Furthermore, PBMC-derived
monocytes were directly co-cultured with brain ECs or GBM-
associated ECs. Flow cytometry analysis showed that co-culture
with GBM-derived ECs, but not normal ECs or CSF-1, induced
robust CD206 expression in CD11b+ macrophages (Fig. 2e).
Finally, we analyzed anti-inflammatory cytokine IL-10 expression
in these treated monocytes, as a function readout for alternative
macrophage activation. Our data showed that co-culture with
GBM ECs remarkably enhanced IL-10 expression in human
monocytes (Fig. 2f), further verifying EC-mediated alternative
macrophage activation in GBM. Taken together, these findings
suggest a vascular niche for alternative polarization of macro-
phages in glioma microenvironment.
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Fig. 1 Alternatively activated macrophages are localized proximately to GBM-associated ECs. a–d Tissue sections from human normal brain and surgical
specimens of human glioma tumors were probed with different antibodies. a GBM tumor sections were stained with anti-CD68 and anti-CD206
antibodies. Representative images are shown (n= 5 GBM patient tumors). Bar represents 100 μm. Zoom-in factor: 4. b GBM tumor sections were stained
with anti-CD68 and anti-CD163 antibodies. Representative images are shown (n= 5 patient GBM tumors). Bar represents 100 μm. Zoom-in factor: 4. c
Normal brain and GBM tumor sections were stained with anti-CD68 and anti-CD206 antibodies. Quantified data are shown (total n= 4 normal brains and
21 glioma tumors, mean± SEM). d GBM tumor sections were stained with anti-CD31, anti-CD206, and anti-CD68 antibodies. Representative images are
shown (n= 5 patient GBM tumors). Arrows indicate CD68+CD206+ cells. Bar represents 100 μm. Zoom-in factor: 4. e, f GBM was induced by RCAS-
mediated gene transfer in Ntv-a;Ink4a-Arf−/−;Ptenfl/fl;LSL-Luc mice, followed by orthotopic tumor transplantation into Rosa-LSL-tdTomato;Tie2-Cre mice. e
Experimental procedure. f Thick sections were stained with anti-F4/80 and anti-CD206 antibodies, and subjected to confocal scanning imaging. 3-D
images were generated and shown. Bar represents 200 μm. Zoom-in factor: 1.6
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EC-secreted IL-6 induces macrophage alternative activation.
We next investigated the mechanism(s) by which GBM-
associated ECs induce macrophage alternative activation,
initially focusing on EC secretion. Multiplex cytokine array ana-
lysis of medium supernatants indicated that glioma-CM
remarkably altered EC expression of multiple cytokines and
growth factors (Fig. 3a). Most robustly up-regulated cytokines
included CCL5 and CXCL5, which regulate macrophage
chemotaxis, and IL-6 and CSF-1, which have known functions
acting on macrophages, particularly considering a recently pub-
lished work showing a role of IL-6 in macrophage alternative
activation in diabetic inflammation26. Our data showed that
CCL5 and CXCL5 did not induce CD206 expression or
macrophage alternative activation (Supplementary Fig. 6).
Immunoblot analysis confirmed that glioma-CM remarkedly
increased IL-6 expression and moderately increased CSF-1
expression in ECs (Fig. 3b), and also showed that GBM-
associated ECs constitutively expressed IL-6 and CSF-1 at a
higher level than normal brain ECs (Fig. 3c). Consistently with
these in vitro results, our in vivo study with an orthotopic, syn-
genetic GL26 glioma model indicated a remarked increase in IL-6
expression by tumor-associated ECs, in comparison to normal
brain ECs (Fig. 3d). Interestingly, IL-6, but not CSF-1, was pre-
ferentially localized in CD31+ ECs, implying that ECs as a major
a
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Fig. 2 GBM ECs induce alternative activation of macrophages. a, b Mouse brain microvascular ECs were pretreated with the glioma-conditioned medium
(glioma-CM, harvested from medium supernatant of mouse GL26 glioma cells under 1% hypoxia) or control medium for 24 h. Mouse bone marrow (BM)-
derived macrophages were incubated with CSF-1 or co-cultured with pretreated ECs for 5 days, stained with anti-CD11b, anti-CD86, anti-CD206
antibodies, and analyzed by flow cytometry. a Representative results of CD206 and CD86 expression in CD11b+ cells. b Quantified data in sorted CD11b+
macrophages (Mϕ, n= 3–4 mice, mean± SEM). c Human brain microvascular ECs were pretreated with the glioma-CM (harvested from medium
supernatant of human U251 glioma cells under 1% hypoxia) or control medium for 24 h. Human peripheral blood mononuclear cell (PBMC)-derived
monocytes were incubated with CSF-1 or co-cultured with pretreated ECs for 5 days, stained with anti-CD11b, anti-CD86, anti-CD206 antibodies, and
subjected to flow cytometry analysis. Quantified data in sorted CD11b+ cells (n= 3, mean± SEM). d Human PBMC-derived monocytes were incubated for
5 days with CSF-1, or co-cultured with tumor-associated ECs isolated from different GBM patients or human normal brain microvascular ECs in upper and
lower chambers of transwells, respectively. Monocytes were harvested and subjected to immunoblot analysis with anti-arginase-1 and anti-GAPDH
antibodies. e Human PBMC-derived monocytes were incubated for 5 days with CSF-1, or co-cultured with tumor-associated ECs isolated from different
GBM tumors (n= 4 patients) or human normal brain microvascular ECs. Cells were harvested, stained with anti-CD206, and anti-CD86 antibodies, and
subjected to flow cytometry analysis. Representative images are shown. f PBMC-derived monocytes were incubated for 5 days with CSF-1, or co-cultured
with tumor-associated ECs isolated from GBM patient #5377 or human normal brain microvascular ECs. Cells were harvested, stained with anti-IL-10 and
anti-CD11b antibodies, and subjected to flow cytometry analysis (n= 5, mean± SEM). P values were determined by Student’s t test
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source for the expression of IL-6 but not CSF-1 in glioma
microenvironment.
We next tested the role of IL-6 in EC-induced macrophage
alternative activation. Our data showed that both IL-6-
neutralizing and CSF-1-neutralizing antibodies reduced CD206+
cell population in CD11b+ mouse BM macrophages treated with
glioma-CM-pretreated ECs, but did not affect CD11b+CD86
+CD206− population (Fig. 4a, b), suggesting a crucial role of IL-6
and CSF-1 in EC-induced alternative macrophage activation.
Consistent with this finding, small interfering RNA (siRNA)-
mediated knockdown of IL-6 in ECs inhibited EC-induced
arginase-1 expression (Supplementary Fig. 7). Interestingly,
treatment of mouse BM-derived macrophages (BMDMs) with
purified IL-6 moderately stimulated CD206 expression, but the
combined treatment with IL-6 and CSF-1 induced alternative
polarization of macrophages, as evidenced by robustly enhanced
CD206+ population in CD11b+ cells (Fig. 4c, d). Consistently, the
combined treatment with IL-6 and CSF-1 increased CD206
population in human PBMC-derived monocytes (Supplementary
Fig. 8). Furthermore, combined treatment with IL-6 and CSF-1,
but not single treatment, remarkably induced arginase-1 expres-
sion (Fig. 4e). Together, these results suggest a role of EC-secreted
IL-6, and possibly microenvironmental CSF-1, for macrophage
alternative activation in GBM.
CSF-1 and IL-6 induce macrophage polarization through HIF-
2α. To explore the mechanisms by which CSF-1 and IL-6 induce
arginase-1 expression and macrophage alternative activation, we
performed a multiplex screening assay for the DNA-binding
activity of 96 transcriptional factors in the treated macrophages.
Unexpectedly, IL-6 treatment alone decreased the activities of
most transcriptional factors (Fig. 5a). However, co-treatment of
CSF-1 and IL-6 activated multiple transcriptional factors,
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including AP1, HIF (hypoxia-inducible factor), KLF4, NF-κB,
and PPAR (peroxisome proliferator-activated receptor) that have
previously been shown critical for macrophage alternative
activation24, 27. In contrast, CSF-1 treatment alone slightly acti-
vated HIF, KLF4, and PPAR, while inactivated AP1 and NF-κB.
Notably, CSF-1 and IL-6 co-treatment remarkably increased the
DNA-binding activity of HIF and PPAR, as indicated by about
70-fold and 80-fold increase in their activity, respectively.
We first tested the role of HIFs in macrophage alternative
activation. HIFs are heterodimers comprising one of three major
oxygen labile HIF-α subunits (HIF-1α, HIF-2α, or HIF-3α), and a
constitutive HIF-1β subunit. HIFs are crucial mediators of
hypoxic response, which transcribe a large number of genes that
promote angiogenesis, anaerobic metabolism, and resistance to
apoptosis, and therefore crucial for cancer development and
progression28–30. We verified the CSF-1- and IL-6-induced HIF
transcriptional activation by HIF-responsive element (HRE)-
driven luciferase expression analysis (Fig. 5b). HIF-1α and HIF-
2α expression is known to be regulated by hypoxia-induced
protein stability, but could also be induced by oxidative stress,
growth factors, and succinate under normoxia31–35. Here we
showed that CSF-1 and IL-6 remarkably increased protein
expression of HIF-2α, but not HIF-1α, under normoxia in mouse
macrophages (Fig. 5c) and human monocytes (Supplementary
Fig. 9). Furthermore, the co-treatment stimulated expression and
nuclei translocation of HIF-2α, but not HIF-1α (Supplementary
Fig. 10), supporting the increased HIF transcriptional activity and
the distinct HIF-2α expression induced by CSF-1 and IL-6.
A recent study suggests a critical role of HIF-2α in macrophage
alternative activation36. Consistently, our data show that short
hairpin RNA (shRNA)-mediated HIF-2α knockdown almost
completely blocked CSF-1-induced and IL-6-induced arginase-1
protein and mRNA expression (Fig. 5c, d) and macrophage
alternative activation (Fig. 5e). In addition, shRNA-mediated
knockdown of IL-6 receptor-α and IL-6 neutralization
significantly inhibited EC-CM-induced PPARγ, HIF-2α, and
arginase-1 expression, suggesting a critical role of IL-6 for
activation of the HIF-2α/arginase-1 axis (Supplementary Fig. 11).
Together, these data identify a critical role of HIF-2α in CSF-1-
induced and IL-6-induced macrophage alternative activation.
PPARγ is required for HIF-2α and arginase-1 expression.
Interestingly, co-treatment with IL-6 and CSF-1, but not either
one alone, remarkably enhanced protein and mRNA expression
of HIF-2α (Fig. 6a, b), suggesting that the co-treatment upregu-
lates HIF-2α expression through modulating HIF-2α transcrip-
tion. We analyzed the promoter sequence of HIF-2α (EPAS1) and
predicted that the transcriptional factors including SP1, PPARγ,
GATA-3, and HOXA9 may possibly bind to the region based on
motif recognition pattern. We explored the regulatory mechan-
ism for HIF-2α transcription with a focus on PPARγ, considering
a robust activation of PPAR induced by the co-treatment (Fig. 5a)
and an established role of PPARγ in macrophage alternative
activation37, 38. Our data indicated that the co-treatment stimu-
lated HIF-2α promoter interaction with PPARγ, as shown by an
immunoprecipitation analysis using synthetic biotin-labeled HIF-
2α promoter DNA (Fig. 6c and Supplementary Fig. 12). More-
over, chromatin immunoprecipitation (ChIP) analysis validated
that IL-6 and CSF-1 co-treatment induced HIF-2α binding to
PPARγ promoter in macrophages (Fig. 6d). Furthermore,
shRNA-mediated knockdown of PPARγ inhibited IL-6 and CSF-
1 co-treatment-induced expression of arginase-1 and HIF-2α
(Fig. 6e), suggesting that PPARγ regulates arginase-1 and HIF-2α
expression in macrophages.
IL-6 induces inflammatory responses via JAK/STAT signaling
and promotes cell survival and growth via MAPK-mediated and
Akt-mediated pathway, respectively. CSF-1 is also known to be
able to activate these survival and growth signaling pathways and
also induces PPARγ activation. We investigated these signaling
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events with time resolution in macrophages co-treated with IL-6
and CSF-1. Co-treatment with CSF-1 increased IL-6-induced
Akt1, Erk, and mTOR signaling activation (Fig. 6f). Furthermore,
treatment with LY294002 and rapamycin, pharmacological
inhibitors of PI3K/Akt and mTOR, respectively, or shRNA-
mediated PPARγ knockdown, inhibited IL-6-induced and CSF-1-
induced macrophage proliferation (Fig. 5g and Supplementary
Fig. 13), suggesting that Akt/mTOR/PPARγ is required for IL-6-
induced and CSF-1-induced macrophage growth. Together, we
propose a model for co-treatment-induced signaling mechanism
for macrophage alternative activation: co-treatment induces
arginase-1 expression through PPARγ and HIF-2α, leading to
macrophage alternative activation, and simultaneously it activates
Akt1/mTOR to promote survival and growth of the alternatively
activated macrophages in the tumor microenvironment.
ECs are one of major sources of IL-6 expression in GBM.
Previous immunohistochemial studies with human GBM speci-
mens suggest tumor-associated ECs and inflammatory cells as the
major sources for IL-6 expression in the tumor microenviron-
ment39. Consistently, we showed that GBM-associated ECs
expressed IL-6 at a relatively higher level, compared with U251
glioma cells, T4123 glioma stem cells, and human PBMC
monocytes (Supplementary Fig. 14). To rigorously investigate the
in vivo role of ECs in IL-6 expression as well as IL-6’s functions in
GBM progression, we generated a conditional IL-6 knockout
Cdh5-CreERT2;Il6fl/fl mouse line, in which IL-6 knockout was
induced by tamoxifen-inducible CreERT2 expression under EC-
specific Cdh5 promoter (Fig. 7a). The efficient and selective
knockout was validated by immunoblot and quantitative reverse
transcription-PCR (RT-PCR) in aortic and brain ECs (Fig. 7b, c
and Supplementary Fig. 15). We took advantage of the ortho-
topic, genetic murine GBM model with a native microenviron-
ment, induced by RCAS/N-tva-mediated somatic PDGF gene
transfer in Ink4a-Arf−/−;Pten−/− neural stem/progenitor cells
(Fig. 7d), followed by tumor transplantation into the new gen-
erated Cdh5-CreERT2;Il6fl/fl mice. Notably, the genetic GBM
mouse model is immunocompetent, which recapitulates the
major features of human GBM including pseudopalisading
necrosis and microvascular proliferation35, 40. Immunoblot ana-
lysis of these tumors reveals that IL-6 deletion in ECs significantly
reduced IL-6 expression in whole tumor lysates (Fig. 7e), con-
firming that ECs are one of major sources of IL-6 expression in
GBM microenvironment.
Endothelial IL-6 is critical for GBM growth and progression.
We finally investigated the in vivo role of endothelial IL-6 in
GBM progression. Our data show that IL-6 deletion in ECs sig-
nificantly improved animal survival in the mice bearing the
genetically induced GBM tumors, leading to an increase in overall
survival time by 45% (19 versus 27.5 days, in control and
tamoxifen-treated Chd5-CreERT2;Il6fl/fl mice, Fig. 8a). Notably,
about 20% of mice survived through the experimental process,
showing no detectable tumors when euthanized at day 50. Con-
sistent with the critical role of endothelial IL-6 in mouse survival,
EC-specific knockout of IL-6 significantly reduced tumor growth,
as indicated by a 70% decrease in average tumor volume (at day
12 after tumor implantation, Fig. 8b). Furthermore, IL-6 knock-
out eliminated pseudopalisades (P) and microvascular prolifera-
tion (MP) in the tumors (Fig. 7c), suggesting a critical role of EC-
derived IL-6 in GBM progression.
Strikingly, IL-6 knockout robustly induced extensive necrosis
and leukocyte infiltration (Fig. 8c), possibly due to its negative
effects on macrophage-mediated tumor immunity. Consistently,
our data showed more neutrophils and CD3+ T cells infiltrated in
the tumors (Supplementary Fig. 16). Flow cytometry analysis of
tumor-associated F4/80+ macrophage cells show that indicated
that IL-6 knockout robustly decreased CD86−CD206+
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macrophage population and slightly increased CD86+CD206−
macrophage population (Fig. 8d, e). Moreover, IL-6 deletion in
ECs increased the expression of proinflammatory IL-12 and
reduced the expression of anti-inflammatory IL-10 (Fig. 8f).
Futhermore, IL-6 deletion did not affect iNOS expression, but
remarkedly inhibited arginase-1 expression in tumor-associated
F4/80+ macrophages (Fig. 8g), supporting the important role of
endothelial IL-6 in macrophage alternative activation. Together,
these data suggest that endothelial cell-derived IL-6 is critical for
macrophage alternative polarization and GBM progression.
Discussion
Our studies identify a vascular niche that drives macrophage
alternative polarization and GBM progression. Namely, tumor-
associated ECs express and release IL-6, jointing with CSF-1 in
the microenvironment, induces HIF-2α-dependent arginase-1
expression through activation of PPAR-γ, leading to macrophage
alternative polarization and GBM progression. IL-6 and CSF-1
also induce mTOR activation, resulting in cell survival and
growth of alternatively activated macrophages in the tumor
microenvironment (Fig. 9).
Macrophages are a crucial player in tumor–host immune
interaction and cancer development and progression. Functional
polarization, for example, M0 (naïve status), M1 (classically
activated), or M2 (alternatively activated), of macrophages
represents a key mechanism that controls their functions,
switching roles between tumor suppressing and promoting4, 5, 41.
Although it has been well established that most of glioma-
associated macrophages acquire alternative activation to execute
tumor-promoting and tumor-immunosuppressive functions23, 42,
recent ex vivo studies based on transcriptome analysis of cytokine
and cell marker expression in isolated myeloid cells suggest that
glioma-associated macrophages exhibit a M0 polarization pro-
file43, suggesting that classical or alternative activation of mac-
rophages depends on the stimulus from tumor microenvironment
and also are possibly not driven by cell plasticity-mediated per-
manent cell fate transition.
Vascular ECs are a major component of tumor micro-
environment. In addition to their classical functions for delivering
oxygen and nutrients to support tumor growth, tumor-associated
ECs act as a niche that fuels tumor growth, progression, and
metastasis by producing paracrine factors, that is, angiocrines, to
tumor microenvironment40, 44–52. For example, it is well known
that perivascular niche is critical for stemness maintenance and
self-renewal in cancer stem cells44, 47, 50. The role of vascular
niche in tumor immunity regulation, nevertheless, remains uni-
dentified. Here our study reveals that EC-derived IL-6 promotes
macrophage alternative activation and GBM progression in vivo,
therefore identifying a vascular niche that controls macrophage
functions in cancer. Supportive to this concept, a recent study
shows that in vitro co-culture with ECs induces differentiation of
hematopoietic progenitor and stimulates macrophage alternative
activation53.
Previous work shows that genetic IL-6 ablation blocks tumor
formation of spontaneous mouse glioma driven by glial fibrillary
acidic protein-mediated expression of viral Src oncogene54. Our
work reveals that EC-derived IL-6 is critical for tumor growth and
progression in a genetically induced GBM mouse model.
Importantly, analyses of TCGA and Rembrandt databases show
that elevated IL-6 expression correlates with poor overall survival
in glioma and GBM patients (Supplementary Fig. 17). Con-
sistently, IL-6 blockade treatment significantly improved animal
survival time by 35% in our genetically engineered GBM model
(17 versus 23 days, in control and anti-IL-6 antibody-treated
mice, Supplementary Fig. 18). Thus, IL-6 blockade may serve as
an efficient strategy for therapeutic intervention of GBM. In
addition, IL-6-deficient mice develop normally55. As such, its EC-
preferential induction in tumor microenvironment, but dis-
pensability in development, suggests that IL-6 may present a
highly selective and non-noxious therapeutic target for cancer
treatment.
Alternative macrophage activation is known to be driven by
multiple cytokines including IL-4 and IL-136, 22. Here we identify
IL-6 as a major driver for alternative macrophage activation in
glioma microenvironment. IL-6 has classically been recognized as
a proinflammatory cytokine56, 57. As such, IL-6 receptor blockade
has been served as an important therapeutic strategy for the
treatment of inflammatory diseases including rheumatoid
arthritis58. Interestingly, IL-6 regulates T cell proliferation and
survival56, 59, induces IL-4 production by CD4+ T cells60, and
promotes T cell Th17 differentiation61. A recent study reports
that IL-6 induces IL-4 receptor expression in macrophages,
leading to their alternative activation in diabetic inflammation26,
suggesting an unexpected role for IL-6 in macrophage-mediated
anti-inflammatory responses. Likewise, our data for the first time
identify IL-6 as a critical instigator of macrophage alternative
activation in cancer. We show that IL-6 and CSF-1 induce robust
arginase-1 expression that primes macrophages to alternative
activation. In addition, previous studies reveal that IL-6 enhances
expression of IL-4 and IL-13, two stimulators for macrophage
alternative activation, likely secreted by T cells60, which may
further promote macrophage alternative activation in the tumor
microenvironment.
Macrophage polarization is subjected to transcriptional reg-
ulation driven by cues in the tissue microenvironment27. Acti-
vation of multiple transcriptional factors, mainly induced by IL-4
IL-6
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Fig. 9 A schematic model. In glioma microenvironment, endothelial cell-derived IL-6 and microenvironmental CSF-1 synergistically activate downstream
Akt1/mTOR pathway and induces transcriptional activation of PPARγ in macrophages (Mϕ), in turn leading to HIF-2α-mediated arginase-1 expression, and
inducing macrophage alternative polarization. The activation of mTOR also induces cell proliferation, contributing to cell survival and growth of alternatively
activated macrophages, eventually leading to glioma progression
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and IL-13, drives macrophage alternative activation, which
includes AP1, HIF-2α, KLF4, PPARγ, and STAT-627, 37, 38, 62,-64.
The mechanisms that control macrophage activation in cancer,
particularly induced by IL-6, remain largely unknown. Here we
reveal that IL-6 and CSF-1 induce PPARγ-dependent HIF-2α
transcription, leading to arginase-1 expression and macrophage
alternative activation in GBM. Interestingly, a recent work that
has screened 270 transcriptional factors shows that PPARγ
coactivator/estrogen-related receptor induces HIF-2α expression
in neuroblastoma, independent of canonical hypoxia-mediated
regulation of protein stability, but through transcription regula-
tion65, supporting our observation of HIF-2α mRNA expression
induced by PPARγ in GBM.
In summary, our study identifies a vascular niche for the reg-
ulation of tumor immunity and reveals an IL-6-mediated
mechanism controlling macrophage alternative activation and
GBM progression. Specifically, IL-6 and CSF-1 induce PPARγ-
dependent HIF-2α transcription, leading to arginase-1 expression
and macrophage alternative polarization in GBM. Thus, targeting
IL-6 may offer exciting therapeutic opportunities to reactivate
macrophage-mediated tumor immunity, which may block tumor
progression and treatment resistance.
Methods
Patient and tumor endothelial cell sorting. All patients received surgery at the
Department of Neurosurgery of the University of Pennsylvania and were enrolled
in a single institution tissue banking protocol that was approved by the University
of Pennsylvania Human Studies Committee. Consent was obtained from all
patients. Tumor-associated ECs were isolated as previously described66. In brief,
tumor-derived single-cell suspensions were prepared by the tissue bank. Red cells
were removed with ACK lysis buffer (Life Technologies). Cell suspension was
subjected to magnetic activating cell sorting (MACS) with anti-CD31 antibody-
conjugated magnetic beads (Miltenyi Biotech, 130-091-935). Sorted ECs were
verified by Dil-Ac-LDL (Bioquote) absorption, and over 99% of cells were Dil-Ac-
LDL-positive.
Cell culture. Human and mouse brain microvascular ECs (ScienCell and Pro-
moCell) were maintained in Endothelial Cell Medium (ECM, ScienCell) at 37 °C in
a humidified air atmosphere with 5% CO2. All cells were used between passages 2
and 5. GL26 mouse glioma cells were kindly provided by Chunsheng Li (University
of Pennsylvania) and cultured in Dulbecco's modified Eagle's medium (DMEM)
medium (Gibco) supplemented with 5% fetal bovine serum (FBS). Chicken DF-1
fibroblasts (ATCC) were maintained in DMEM medium (ATCC, 30-2002) con-
taining 5% FBS at 39 °C in a humidified air atmosphere with 5% CO2. T4123
glioma stem cells were kindly provided by Jeremy Rich (Cleveland Clinic) and then
cultured in serum-free Neurobasal-A medium (Gibco), supplemented with B-27
Supplement Minus Vitamin A (Gibco), GlutaMax (Gibco), sodium pyruvate
(Gibco), fibroblastic growth factor (5 ng/ml, R&D Systems), and EGF (20 ng/ml,
R&D Systems). All cancer cell lines were checked and showed no mycoplasma
contamination.
Mice. Wild-type (WT) mice on the C57BL/6J background were obtained from
Jackson Lab. Cdh5-CreERT2 mice were generated by Ralf Adams (Max Planck) and
kindly provided by Nancy Speck (University of Pennsylvania) and Bisen Ding
(Cornell)67. Il6fl/fl mice have been described previously68, 69. Cdh5-CreERT2;Il6fl/fl
mice were generated by crossing Il6fl/fl mice with Cdh5-CreERT2 mice. Mice were
genotyped with primers including IL-6 FP: 5′-CCCACCAAGAACGATAGTCA-3′,
and IL-6 RP: 5′-GGTATCCTCTGTGAAGTCCTC-3′. Cdh5-CreERT2;Il6fl/fl and
Il6fl/fl mice (2 weeks old) were intraperitoneally injected with 0.1 ml of 5 mg/ml
tamoxifen daily for consecutive 5 days. Rosa-LSL-tdTomato;Tie2-Cre mice were
generated by crossing Rosa-LSL-tdTomato mice (Jackson Lab) with Tie2-Cre mice
(Jackson Lab). All animal studies were reviewed and approved by the Institutional
Animal Care and Use Committees (IACUC) at the University of Pennsylvania. All
animals were housed in the Association for the Assessment and Accreditation of
Laboratory Animal Care-accredited animal facility of the University of
Pennsylvania.
Isolation and culture of mouse ECs. Mouse aortic ECs were isolated from Cdh5-
CreERT2;Il6fl/fl mice as previously described35. In brief, thoracic aorta was isolated
from 3-week-old mice and cut into pieces. Aortic rings were embedded in
phosphate-buffered saline (PBS)-prewashed Matrigel and then incubated in
DMEM/F-12 medium containing 5% FBS for 5 days. After rinsing with PBS, the
rings were removed and the remaining cells were incubated with 2 U/ml Dispase I
(Gibco, 17105-041) for 20 min at 37 °C. After centrifugation at 500 × g for 10 min,
the cell pellets were washed with PBS. ECs were also isolated from mouse brain.
Single-cell suspension was prepared and subjected to MACS with anti-CD31
antibody-conjugated magnetic beads (Miltenyi Biotech, 130-091-935). Cells were
cultured in DMEM/F-12 medium supplemented with 25 μg/ml EC growth sup-
plement (Sigma) and 5% FBS. All cells were used between passages 2 and 4.
Genetic GBM mouse model. GBM was induced in mice as previously described66.
In brief, chicken DF-1 fibroblasts (ATCC) were transfected with RCAS-PDGF-B
and RCAS-Cre plasmids to produce retrovirus, and orthotopically injected into
Ntv-a;Ink4a-Arf−/−;Ptenfl/fl;LSL-luc mice to induce GBM through RCAS/n-tva-
mediated gene transfer. Tumors were isolated and subjected to mechanical dis-
sociation with a gentleMACS Dissociator (Miltenyi Biotech) and enzymatic
digestion with collagenase II and dispase II to obtain single-cell suspensions. About
8 weeks old Cdh5-CreETR2;Il6fl/fl and Il6fl/fl mice, half male and half female, were
orthotopically and stereotactically injected with 105 GBM tumor cells that express
luciferase. Tumor growth was monitored by whole-body bioluminescence using an
IVIS 200 Spectrum Imaging System after retro-orbital injection of luciferin (150
mg/kg, GoldBio). Survival was monitored for 50 days. For antibody treatment
experiment, tumor-bearing mice were intraperitoneally treated with anti-CSF-1
(BioXcell, BE0204, 1 mg per mouse x 4) or anti-IL-6 (BioXcell, BE0046, 200 μg per
mouse x 4) antibody or control rat immunoglobulin G (IgG) (BioXcell, BE0090,
200 μg per mouse x 4). Mice were euthanized when exhibiting severe GBM
symptoms including domehead, hemiparesis, or more than 20% of body weight
loss. Mice were randomized to receive treatment, and the investigators were not
blinded.
GL26 glioma mouse model. GL26 glioma was induced in mice as previously
described66. In brief, about 8 weeks old Rosa-LSL-tdTomato;Tie2-Cre and WT mice
were orthotopically and stereotactically injected with 105 GL26 mouse glioma cells
that express luciferase. Tumor growth was monitored by whole-body biolumi-
nescence using an IVIS 200 Spectrum Imaging System after retro-orbital injection
of luciferin (150 mg/kg, GoldBio).
Preparation of glioma-CM. Mouse GL26 glioma cells or Human U251, U87, and
IN528 glioma cells were cultured with DMEM medium supplemented with 5%
FBS. Cells at about 90% confluence were exposed to hypoxia (1% O2) in a
humidified air atmosphere at 37 °C for 24 h. Culture medium were centrifuged at
5,000 × g for 30 min to remove cellular debris and then the supernatant was
collected.
Preparation of EC-CM. Human normal brain microvascular ECs (ScienCell and
PromoCell) and GBM patients' tumor-derived ECs (#5377, #5441, #5391, #5465)
were maintained with ECM (ScienCell). When reaching about 70% confluence,
cells were cultured at 37 °C for 24 h. Culture medium were centrifuged at 5,000 × g
for 30 min to remove cellular debris and then the supernatant was collected.
BMDM isolation and treatment. Freshly isolated femur and tibia from WT
C57BL/6 mice were flushed with RPMI-1640 medium (Life Technologies). Cells
were harvested and passed through a 40-μm strainer. Red cells were removed with
ACK lysis buffer. BM cells were cultured in RPMI-1640 medium supplemented
with 5% FBS (Life Technologies). Cells were incubated with 10 ng/ml human CSF-
1 (BioLegend, 574808) for 7 days to induce macrophage differentiation. Cells were
treated with 100 ng/ml mouse IL-6 (BioLegend, 575708) and CSF-1 for different
times.
Human peripheral blood-derived monocytes and treatment. Primary human
monocytes, purchased from the Human Immunology Core at the University of
Pennsylvania, were isolated from healthy volunteer donors following leukapheresis
by negative selection. All specimens were collected under a University Institutional
Review Board-approved protocol, and written informed consent was obtained from
each donor. Isolated cells were incubated in RPMI-1640 medium supplemented
with 5% heat-inactivated FBS. Cells were treated with 10 ng/ml human CSF-1, 100
ng/ml human IL-6 (BioLegend, 570808), and normal human ECs or patient tumor
EC-CM.
Co-culture of BM cells and ECs and treatment. Mouse BM cells were co-cultured
with mouse brain microvascular ECs, CCL5 (PeproTech, 250-07), or CXCL5
(PeproTech, 300-22) under normoxia or hypoxia (1% O2). ECs were seeded in 6-
well plates (5 × 103/well) and then cultured overnight with DMEM medium con-
taining 5% FBS, followed by treatment with glioma-CM as described above. ECs
were washed with PBS and co-cultured with freshly prepared BMDMs (104 cells
per well) for 5 days in RPMI-1640 media supplemented with 5% FBS. Cells were
treated with specific neutralizing antibodies against CSF-1 (1 μg/ml, R&D Systems,
AF416) and IL-6 (1 μg/ml, BioLegend, 504505), or control IgG (Sigma). Cells were
fixed and subjected to immunofluorescence analysis. Single-cell suspension was
prepared by using Versene solution (0.02% EDTA, Thermo) and then subjected to
flow cytometry analysis.
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shRNA and siRNA treatment. The 293T cells (ATCC) were co-transfected with
packaging vectors (System Biosciences) and lentiviral expression vectors that
encode shRNA targeting HIF-1α and HIF-2α (kindly provided by Celeste Simon as
previously published70), and PPARγ (Sigma, TRCN0000001657,
TRCN0000001660, and TRCN0000025967) for 8 h. For IL-6R-α knockdown, the
oligonucleotides (#1: sense, 5′-TACCGACCTGTATGGTCAAATTCAAGAGAT
TTGACCATACAGGTCGGTTTTTTTC-3′, and antisense, 5′-TCGAGAAAAAAA
CCGACCTGTATGGTCAAATCTCTTGAATTTGACCATACAGGTCGGTA-3′;
#2: sense: 5′-TATCAGTACGAAAGTTCTACTTCAAGAGAGTAGAACTTTCGT
ACTGATTTTTTTC-3′, antisense, 5′-TCGAGAAAAAAATCAGTACGAAAGTTC
TACTCTCTTGAAGTAGAACTTTCGTACTGATA-3′; #3: sense, 5′-TCAATAC
CGTAAACCACAGCTTCAAGAGAGCTGTGGTTTACGGTATTGTTTTTTC-3′,
antisense, 5′-TCGAGAAAAAACAATACCGTAAACCACAGCTCTCTTGAAG
CTGTGGTTTACGGTATTGA-3′) that encode shRNAs were synthesized and
cloned into the pSicoR lentivirus expression vector, followed by transfection with
293T cells. After change with fresh medium and incubation for 48 h, medium
supernatants containing lentivirus were collected. Freshly separated BMDMs were
infected with lentivirus in the presence of 8 μg/ml polybrene (Millipore). Stably
shRNA-expressing cells were selected with 1.8 μg/ml puromycin and maintained in
the culture medium with 0.5 μg/ml puromycin. Cells were transfected with control
or IL-6 siRNA (Ambion, 4390771) by using Lipofectamine 2000 (Invitrogen).
Dual luciferase reporter assay. WT or mutated HRE with firefly luciferase
reporter in pGL2 (kindly provided by Celeste Simon) were subcloned into lenti-
virus expression vector pCDH (System Biosciences). The 293T cells (ATCC) were
co-transfected with packaging vectors (System Biosciences) and lentiviral expres-
sion vectors that express HRE-luciferase or control CMV-renilla luciferase. Freshly
prepared BMDMs were treated and transduced with lentivirus, followed by mea-
surement of luciferase activity using a Dual Luciferase Assay System (Promega).
Each measured firefly luciferase activity was normalized by the renilla luciferase
activity in the same well.
Transcription factor activation profiling array. BMDMs were treated with dif-
ferent cytokines. Nuclear proteins were isolated with a nuclear extraction kit
(Signosis, SK-0001), and analyzed by using a 96-well plate transcription factor (TF)
activation array (Signosis, FA1002) according to the manufacturer’s instruction.
The activity of each transcriptional factor was normalized as the fold of TFIID’s
activity.
Chromatin immunoprecipitation. ChIP assays were performed using a Magna
ChIP kit (Millipore, MAGNA0001) according to the manufacturer’s instructions.
Mouse BM cells (107 cells) cultured in 15-cm dishes were treated with CSF-1 and
IL-6. Cells were crosslinked with 1% formaldehyde for 10 min at room tempera-
ture, followed by glycine incubation for 5 min. The cells were sonicated three times,
each for 16 s, using a W-385 sonicater (Heat Systems Ultrasonics). Immunopre-
cipitants with chromatin were prepared by using 20 μg anti-PPARγ (Santa Cruz,
sc-7196) or anti-normal rabbit IgG (Santa Cruz, sc-2027) with cell lysates from 106
cells in 0.5 ml reaction buffer. The primers pairs for HIF-2α promoter used in the
ChIP-PCR and ChIP-qRT-PCR are listed as followings: Primer #1: FP, 5′-TACAG
CTCAAATCCAGCAGAAGC-3′, RP, 5′-GAGGGAGGGAAAGACCAGACAA-
TAA-3′; Primer #2: FP, 5′-GCTTTCTCCGCAATTCACAACTATG-3′, RP, 5′-TCT
TAGACACTTTCCCATTTCCTACTT-3′; Primer #3: FP, 5′-CGCCATTACTCAG
TCCTGCGCTAA-3′, RP, 5′-TTCCGCAGAACTGCGACTTGTTT-3′.
Cytokine array. Human brain microvascular ECs were treated with glioma-CM or
control medium for 24 h at 37 °C. After washing twice with PBS, cells were
incubated with DMEM/F-12 medium supplemented with 2% bovine serum albu-
min (Sigma) for 12 h. Cell lysates were subjected to multiplex cytokine analysis
using a Human XL Cytokine Array (Ary022, R&D Systems) according to the
manufacturer's instructions.
Quantitative RT-PCR analysis. Total RNA was isolated using TRIzol reagent
(Invitrogen) from treated mouse BMDMs, mouse aortic ECs, and mouse liver
tissue. RNA was reversely transcribed using SuperScript III First-Strand Synthesis
SuperMix (Life Technologies), and subjected to real-time PCR analysis using
TaqMan® Fast Universal PCR Master Mix (Life Technologies) and primers: HIF-1α
(Applied (Biosystems, Mm00468869_m1), HIF-2α (EPAS1, Applied Biosystems,
Mm00438717_m1), IL-6 (Applied Biosystems, Mm00446190_m1), and arginase-1
(FP: 5′-CTCCAAGCCAAAGTCCTTAGAG-3′; RP: 5′-GCATCCACCCAAATGA
CACAT-3′). Quantitative RT-PCR was performed in a 20-μl reaction volume using
Fast SYBR Green Master Mix (Applied Biosystems) with 18S rRNA or glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) used as endogenous controls.
Immunofluorescence and histology. Human surgical specimens from subjects
with glioma or normal brain tissues (from US Biomax, BioChain, and from patients
treated in Department of Neurosurgery, Sun Yat-sen University Cancer Center,
China. Patient specimens were collected under a University Institutional Review
Board-approved protocol, and written informed consent was obtained from each
patient), or mouse tumors tissues were used. Paraffin sections were de-paraffinized
and rehydrated, and subjected to antigen retrieval in Target Retrieve Solution
(Dako, S1699) at 95 °C for 20 min. Sections were blocked with 5% horse serum for
1 h at room temperature. Human samples were incubated with anti-CD31 (1:100,
Cell Signaling, 3528), anti-CD68 (1:100, Cell Signaling, 76437), anti-CD86 (1:100,
BD Pharmingen, 555656), anti-CD163 (1:100, Serotec/Bio-Rad, MCA1853T), anti-
CD206 (1:100, Santa Cruz, SC376108), anti-arginase-1 (1:100, Santa Cruz,
SC20150), or anti-iNOS (Abcam, ab3523) antibody overnight at 4 °C. For mouse
tissues, sections were incubated with anti-CD31 (1:100, Dianova, DIA310), anti-IL-
6 (1:100, Dako, A0082; Novus, NB600-1131), anti-CSF-1 (1:100, Millipore,
AB5320), anti-F4/80 (1:100, Miltenyi Biotech, 130-102-379), anti-arginase-1 (1:100,
Santa Cruz, SC-18354), anti-Mac3 (1:100, BD Pharmingen, 550292), anti-CD3
(1:100, Abcam, ab11089), anti-CD8 (1:100, Cell Signaling, 98941), or anti-
neutrophil (1:100, Cedariane, CL8993B) antibody overnight at 4 °C. For cell cul-
ture, cells were fixed with 4% paraformaldehyde for 10 min and incubated with
anti-CD11b (1:100, BioLegend, 101206), anti-arginase-1 (1:100, Santa Cruz, sc-
18354), or anti-iNOS (Abcam, ab3523) antibody. Sections were stained with Alexa
Fluor® 488-conjugated, 568-conjugated, and 647-conjugated appropriate secondary
IgGs (1:500, Life Technologies) for 1 h at room temperature. Images were acquired
with an AxioImager fluorescence microscope (Zeiss) equipped with AxioCam 506
CCD camera (Zeiss). For histological study, sections were stained with hematoxylin
and eosin (H&E), and imaged with an AxioLab microscope (Zeiss) equipped with
AxioCam HRC CCD camera (Zeiss).
Brain tissue preparation and 3-D confocal imaging. The Rosa-LSL-tdTomato;
Tie2-Cre mice bearing RCAS-induced tumors were perfused with 30 ml PBS and
10 ml 4% paraformaldehyde. The brains were dissected and fixed in 4% paraf-
ormaldehyde for 24 h at 4 °C. Hydrogels were prepared by using 40% acrylamide
and 10% VA-044 in PBS. The brain was soaked in the hydrogel for 24 h at 4 °C,
followed by polymerization in hydrogel at 37 °C for 3 h. The brains were cut into 2-
mm-thick slices. The brain slices were placed in a holder and cleared for 3 h by
electrophoretic tissue clearing with the X-CLARITY Tissue Clearing system (Logos
Biosystems, C10001). The cleared brain slices were washed in PBS overnight, and
incubated with FITC-conjugated anti-F4/80 antibody (1:100) and Alexa Fluor 647-
conjugated anti-CD206 antibody (1:100) in PBS for 1 day at 37 °C. After washing
with PBS for 1 day, the brain slices were incubated in the X-CLARITY mounting
solution (Logos Biosystems, C13101) at 37 °C for 1 day. The slices were placed on
the glass slide for confocal imaging with an SP8 laser microscope (Leica) in the
Microscopy Core of the University of Pennsylvania. 3-D images were generated by
using the Velocity software.
Immunoblot analysis. Cells and tissues were lysed with a NP-40 buffer containing
protease inhibitor cocktail (Roche, 11697498001). Protein (20–50 μg0 was resolved
by 4–15% precast sodium dodecyl-sulfate polyacrylamide gel electrophoresis gel
(Bio-Rad). After transfer, PVDF membranes were blotted with anti-GAPDH
(1;1,000, Cell Signaling, 5174), anti-PCNA (1:1,000, Origene, TA800875), anti-
mouse arginase-1 (1:1,000, Santa Cruz, sc-18354), anti-human IL-6 (1:1,000,
GeneTex, GTX110527), anti-mouse IL-6 (1:1,000, Cell Signaling, 12912), anti-α-
tubulin (1:1,000, Cell Signaling, 2144), anti-human CSF-1 (1:1,000, Abcam,
ab9693), anti-HIF-1α (1:1,000, Cayman, 10006421), anti-HIF-2α (1:1,000, Origene,
TA309641), anti-PPARγ (1:1,000, Cell Signaling, 2443), anti-P-Akt-Ser473 (1:1,000,
Alzforum, AB3132), anti-Akt (1:1,000, Cell Signaling, 4685), anti-P-ERK1/2-
Thr202/Tyr204 (1:1,000, Cell Signaling, 4370), anti-ERK1/2 (1:1,000, Cell Signaling,
4695), anti-P-mTOR-Ser2448 (1:1,000, Cell Signaling, 5536), anti-mTOR (1:1,000,
Cell Signaling, 2983), or anti-HSP90 (1:1,000, Cell Signaling, 4874) antibody.
Proteins were detected with horseradish peroxidase-conjugated antibodies specific
for either rabbit or mouse IgG (Bio-Rad), followed by ECL development (GE
Healthcare, RPN2232). Band density was quantified by using NIH Image J pro-
gram. The uncropped blots were included as in Supplementary Fig. 19.
Flow cytometry. Mouse glioma and normal brain tissues were isolated and sub-
jected to mechanical dissociation with a gentleMACS Dissociator (Miltenyi Bio-
tech) and enzymatic digestion with collagenase II and dispase II. The single-cell
suspensions were prepared from mouse tumors and brains, BMDMs cells, and
human BMDMs with or without co-culture with ECs. A total of 2 × 106 cells were
probed with anti-CD11b (1:100, BioLegend, 101206), anti-CD86 (1:100, BD Phar-
mingen, 553692), anti-CD206 (1:100, BioLegend,141708), anti-mouse IL-10 (1:100,
BioLegend, 505009), anti-mouse IL-12 (1:100, BioLegend, 505203), or anti-human
IL-10 (1:100, BioLegend, 506807) antibody with conjugation with different fluor-
escence dyes, or control IgG. The cells were analyzed with an Accuri C6 flow
cytometer (BD Biosciences) by using FlowJo software.
Statistical analysis. Student’s t test (unpaired, two-tailed) and log-rank
(Mantel–Cox test) analysis were performed by using Prism software for statistical
analysis between groups, and p < 0.05 was considered to represent a statistically
significant difference.
Data availability. All data are available within the Article and Supplementary Files,
or available from the authors upon request.
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